7 hours ago
Following through on its significant investment commitment in China, AstraZeneca on Thursday announced plans to build a commercial cell therapy manufacturing facility and an innovation center focused on this modality in Shanghai. This initiative is part of AstraZeneca's broader $15 billion investment commitment in the country.
